-
Efficacy and Safety of Lersivirine Versus Etravirine for the
Treatment of HIV-1 Infection in Patients with Prior
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use
and Evidence of NNRTI Resistance: A Randomized Phase 2B
Trial.
DeJesus E, Fätkenheuer G, Orrell C, et al
HIV Clin Trials.
2014 Jan 1;15(5):209-217.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Lersivirine - a new drug for HIV infection
therapy.
Platten M,
Fätkenheuer G.
Expert
Opin Investig Drugs.
2013 Oct 16
Abstract
-
Pharmacokinetic interactions between
lersivirine and zidovudine, tenofovir disoproxil
fumarate/emtricitabine and abacavir/lamivudine.
Vourvahis M, Davis J, Langdon G, et al
Antivir Ther.
2013 Apr 4.
Abstract
-
Efficacy and Safety of Lersivirine
(UK-453,061) Versus Efavirenz in Antiretroviral
Treatment-Naive HIV-1-Infected Patients: Week 48 Primary
Analysis Results From an Ongoing, Multicenter, Randomized,
Double-Blind, Phase IIb Trial.
Vernazza P,
Wang C, Pozniak A,
et al
J Acquir Immune Defic Syndr.
2013 Feb 1;62(2):171-179.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and Safety of Lersivirine
(UK-453,061) versus Efavirenz in Antiretroviral
Treatment-Naïve HIV-1-Infected Patients: Week 48 Primary
Analysis Results from an Ongoing, Multicenter, Randomized,
Double-Blind, Phase IIb Trial.
Vernazza P, Wang C, Pozniak A, et al
J Acquir Immune Defic Syndr.
2012 Oct 31.
Abstract
-
Effect of lersivirine co-administration on
pharmacokinetics of methadone in healthy volunteers.
Vourvahis M, Wang R, Gruener DM, , et al
Drug
Alcohol Depend. 2012
Jun 8.
Abstract
-
The Pharmacokinetics of Lersivirine (UK-453,061) and HIV-1
Protease Inhibitor Coadministration
in Healthy Subjects.
Vourvahis M, Langdon G, Layton G,
et
al
J Acquir Immune Defic Syndr.
2012 May 1;60(1):24-32
Abstract
-
No Effect of a Single Supratherapeutic Dose of
Lersivirine, a Next-Generation Nonnucleoside Reverse
Transcriptase Inhibitor, on Corrected QT Interval in Healthy
Subjects.
Vourvahis M, Wang R, Ndongo MN, et al
Antimicrob Agents Chemother.
2012 May;56(5):2408-13.
Abstract
-
Developmental Toxicity Study of Lersivirine in Mice.
Cappon GD, Bowman CJ, Campion SN, et al
Birth Defects Res B Dev Reprod Toxicol.
2012 Mar 22.
Abstract
-
Pharmacokinetic Effects of Co-Administration of Lersivirine with Raltegravir
or Maraviroc
in Healthy Subjects.
Vourvahis M, Langdon G, Labadie RR, et al
Antimicrob Agents Chemother. 2011 Nov
28
Abstract
-
Comparison of the non-nucleoside reverse transcriptase
inhibitor lersivirine with its pyrazole and imidazole
isomers.
Jones LH, Allan G, Corbau R,
Chem Biol Drug Des.
2011 May;77(5):393-7
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
Safety and tolerability of lersivirine, a nonnucleoside reverse
transcriptase inhibitor, during a
28-day, randomized, placebo-controlled, Phase I clinical study in
healthy male volunteers.
Davis J, Hackman F, Ndongo MN, et al
Clin Ther.
2010
Oct;32(11):1889-95
Paper
-
A WEEK-IN-REVIEW FEATURED REPORT
Lersivirine: a Non-Nucleoside Reverse Transcriptase Inhibitor with
Activity
against Drug-Resistant Human Immunodeficiency Virus-1.
Corbau R, Mori J, Phillips C, et al
Antimicrob Agents Chemother.
2010 Jul 26.
Abstract
-
FULL-TEXT ARTICLE
Excretion and
metabolism of lersivirine
(5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile),
a next-generation non-nucleoside reverse transcriptase inhibitor, after
administration of [14C]Lersivirine to healthy volunteers.
Vourvahis M, Gleave M, Nedderman AN,
et al
Drug Metab Dispos. 2010
May;38(5):789-800
Paper
-
A WEEK-IN-REVIEW FEATURED REPORT
Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a
next-generation
nonnucleoside reverse transcriptase inhibitor, during 7-day
monotherapy in HIV-1-infected
patients.
Fätkenheuer G, Staszewski S, Plettenburg A, et al
AIDS. 2009 Sep
23
Abstract
-
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a
development candidate.
Mowbray CE, Burt C, Corbau R, et al
Bioorg Med Chem Lett.
2009 Oct 15;19(20):5857-60
Abstract
|
New
and Noteworthy
ARV Investigational
Drugs Main Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader